Toumy Guettouche, PhD, chief scientific officer at Mercy BioAnalytics and a study co-author, discusses how a blood test measuring proteins on extracellular vesicles detected signs of early-stage ovarian cancer before diagnosis—and what researchers still need to establish before the approach could be used for routine screening.
A peer-reviewed study found that the platform identified 57% more proteins than bulk methods and differentiated hepatocellular carcinoma from cirrhosis in plasma samples.
Renew Biotechnologies and Mayo Clinic have partnered to evaluate NeuroLens, a cfDNA-based test, for monitoring central nervous system injury and disease progression in multiple sclerosis and related neuroimmunologic conditions.
General practitioner requests for AMH fertility tests rose more than 13-fold from 2011 to 2021, despite research showing these tests cannot predict natural conception, according to a Flinders University study of 1.4 million health records.
Read More
5Q Spectra plans to launch the Prostate Dx blood test, designed to help assess prostate cancer risk after elevated PSA results and potentially reduce unnecessary biopsies.
Read More
Labcorp has acquired MLM Medical Labs, expanding its central laboratory network to four continents and strengthening biomarker and specialty testing capabilities for clinical trials, according to a company announcement.
Read More
AI models analyzing routine H&E slides can identify genomic alterations and immune patterns in NSCLC, supporting biomarker discovery and patient stratification, according to studies to be presented by Lunit at WCLC 2026.
Read More
Kumamoto University researchers have developed a blood test that analyzes nucleosome structures in cell-free DNA to detect breast cancer recurrence.
Read More
A study validates Nu.Q NETs H3.1 nucleosomes as independent predictors of 28-day mortality and renal replacement therapy need in sepsis and septic shock, according to VolitionRx.
Read More
Humanity Health and Quest Diagnostics have launched a biological age analysis add-on for select health profile tests in the US, allowing users to assess aging biomarkers using routine blood samples.
Read More
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
Read More
The FDA has cleared Roche’s Elecsys pTau217 blood test to aid in identifying Alzheimer disease amyloid pathology, marking the first single-biomarker assay for both rule-in and rule-out use on existing lab instruments.
Read More
The FDA has cleared the first blood-based Alzheimer’s test authorized for symptomatic adults as young as 40.
Read More
Amsbio has launched synthetic cell mimic controls for flow cytometry, aiming to improve lot-to-lot consistency and reproducibility in diagnostics and cell therapy manufacturing.
Read More
Tel Aviv University researchers have developed a low-cost blood test that detects lung cancer by analyzing optical DNA fingerprints, achieving 93.1% sensitivity and 90.3% specificity.
Read More
Researchers at MUSC Hollings Cancer Center have developed the ADLiB liquid biopsy platform, which uses machine learning to prioritize lymphoma diagnosis, identifying high-risk patients with up to 95% accuracy.
Read More
VolitionRx has published peer-reviewed data on its Capture-Seq technology, reporting over 99% pure ctDNA isolation from plasma and 95% detection of early-stage cancers in validation cohorts.
Read More
Caris Life Sciences has launched in-house PTEN IHC testing to identify prostate cancer patients eligible for FDA-approved, biomarker-guided therapy, supporting precision treatment for PTEN-deficient mAPMN/S prostate cancer.
Read More